• 17Mar2026
    [[TitleNews]]
    How Baloxavir API Changes Influenza Treatment Rules?
    We supply high-purity Baloxavir API, a novel cap-dependent endonuclease inhibitor for influenza with anti-resistance, single-dose efficacy, and dual treatment-prophylaxis benefits. Strict cGMP production, crystallinity & impurity control, ICH-compliant data and DMF support for pharmaceutical partners.
    read more
  • 17Mar2026
    [[TitleNews]]
    7 Game-Changing Benefits of Retatrutide Powder API Today

    This article explores the 7 key benefits of Retatrutide powder API, a triple-receptor agonist, including its superior weight-loss and type 2 diabetes management effects, relief of obesity-related complications, impact on fatty liver, side effects, advantages of powder form for global distribution, and reasons to choose Shaanxi Sunrise as the supplier, backed by Phase 3 clinical data and professional pharmaceutical insights.

    read more
  • 17Mar2026
    [[TitleNews]]
    7 Critical Advantages of Baloxavir API for Treatment
    This article outlines 7 critical advantages of Baloxavir API for influenza treatment, covering its unique mechanism against drug resistance, single-dose convenience, broad-spectrum activity, excellent safety, strict quality compliance, prophylaxis efficacy, and reliable supply from Shaanxi Sunrise Pharmaceutical.
    read more